ROS1 and non-small cell lung carcinoma: Regarding non-small-cell lung cancer (NSCLC), multiple studies have shown that patients with rearrangements in the anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) genes are at an increased risk of VTE events [70,71,72,73,74].